This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (10)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Arch Ophthalmol. 2002;120:1225-1227.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Lymphoid tumors are the most common primary orbital malignancy.^1-2 However, they constitute only about 2% of all nodal and extranodal lymphomas.³ Most published reports advocate the use of external beam radiotherapy or systemic chemotherapy for the treatment of orbital lymphoma.^4-7 Recent reports have suggested that immunotherapy may also be effective in the treatment of low-grade non-Hodgkin lymphoma (NHL).^8-10 We describe 4 patients in whom orbital NHL was treated effectively with immunotherapy using anti-CD20 monoclonal antibodies. To our knowledge, there are no previously published reports of monoclonal antibody therapy for NHL of the orbit.

Report of Cases

Between October 1999 and May 2001, 4 patients with the diagnosis of NHL of the orbit were treated at our institution with immunotherapy using monoclonal antibodies to CD20. When initially examined by us, all 4 patients had orbital lymphoma as a secondary extranodal site of involvement of previously diagnosed NHL. For each patient, clinical records and imaging . . . [Full Text of this Article]

Comment
Corresponding author: Bita Esmaeli, MD, Ophthalmology Section, Department of Plastic Surgery, Box 443, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 (e-mail: besmaeli@mdanderson.org).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prevalence and Nature of Systemic Involvement and Stage at Initial Examination in Patients With Orbital and Ocular Adnexal Lymphoma
Hatef et al.
Arch Ophthalmol 2007;125:1663-1667.
ABSTRACT | FULL TEXT